Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-Cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (AHUS)

Read also

uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate

Agency torpedoes company's plans to submit BLA for gene therapy AMT-130 in Q1 2026.

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn.

Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges

Femasys (FEMY) on Monday said that the FDA  approved continuation of the final phase of its FemBloc pivotal trial, sending shares 25% higher in premarket trading.

Praxis announces

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback